Patents Assigned to Idera Pharmaceuticals, Inc.
  • Patent number: 7824696
    Abstract: The invention relates to the therapeutic use of oligonucleotides or oligonucleotide analogs as immunostimulatory agents in immunotherapy applications. The invention provides methods for enhancing the immune response caused by immunostimulatory oligonucleotide compounds.
    Type: Grant
    Filed: October 27, 2003
    Date of Patent: November 2, 2010
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Qiuyan Zhao, Dong Yu, Sudhir Agrawal
  • Patent number: 7812000
    Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5? end.
    Type: Grant
    Filed: October 3, 2007
    Date of Patent: October 12, 2010
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Sudhir Agrawal, Ekambar R. Kandimalla, Dong Yu, Lakshmi Bhagat
  • Patent number: 7790168
    Abstract: The invention relates to the therapeutic use of oligonucleotides or oligonucleotide analogs as immunostimulatory agents in immunotherapy applications. The invention provides methods for enhancing the immune response caused by immunostimulatory oligonucleotide compounds.
    Type: Grant
    Filed: October 27, 2003
    Date of Patent: September 7, 2010
    Assignee: Idera Pharmaceuticals, Inc
    Inventors: Ekambar R. Kandimalla, Qiuyan Zhao, Dong Yu, Sudhir Agrawal
  • Patent number: 7786089
    Abstract: The invention provides a palindromic immune modulatory nucleic acid. The invention also provides methods for generating, enhancing and modifying the immune response caused by palindromic immune modulatory compounds used for immunotherapy applications.
    Type: Grant
    Filed: December 19, 2006
    Date of Patent: August 31, 2010
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Mallikarjuna Reddy Putta, Sudhir Agrawal
  • Publication number: 20100215642
    Abstract: The invention relates to the therapeutic use of novel stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides novel RNA-based oligoribonucleotides with improved nuclease and RNase stability and that selectively induce immune modulatory activity through TLR7.
    Type: Application
    Filed: February 10, 2010
    Publication date: August 26, 2010
    Applicant: IDERA PHARMACEUTICALS, INC.
    Inventors: Tao Lan, Ekambar Kandimalla, Daqing Wang, Sudhir Agrawal
  • Patent number: 7776834
    Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides an immunostimulatory oligonucleotides for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunostimulatory oligonucleotides of the invention preferably comprise novel purines. The immunostimulatory oligonucleotides according to the invention further comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5? end.
    Type: Grant
    Filed: November 7, 2005
    Date of Patent: August 17, 2010
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Sudhir Agrawal, Dong Yu, Ekambar Kandimalla
  • Patent number: 7749975
    Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5? end.
    Type: Grant
    Filed: July 1, 2005
    Date of Patent: July 6, 2010
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Sudhir Agrawal, Ekambar R. Kandimalla, Dong Yu, Lakshmi Bhagat
  • Patent number: 7713535
    Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5? end.
    Type: Grant
    Filed: May 24, 2004
    Date of Patent: May 11, 2010
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Sudhir Agrawal, Fu-Gang Zhu, Ekambar R. Kandimalla
  • Publication number: 20100111936
    Abstract: Antisense oligonucleotide compounds, compositions and methods are provided for down regulating the expression of TLR4. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding TLR4. The compositions may also comprise antisense oligonucleotides targeted to nucleic acids encoding TLR4 in combination with other therapeutic and/or prophylactic compounds and/or compositions. Methods of using these compounds and compositions for down-regulating TLR4 expression and for prevention or treatment of diseases wherein modulation of TLR4 expression would be beneficial are provided.
    Type: Application
    Filed: November 4, 2009
    Publication date: May 6, 2010
    Applicant: IDERA PHARMACEUTICALS, INC.
    Inventors: Mallikarjuna Putta, Ekambar Kandimalla, Lakshmi Bhagat, Daqing Wang, Dong Yu, Sudhir Agrawal
  • Publication number: 20100111937
    Abstract: Antisense oligonucleotide compounds, compositions and methods are provided for down regulating the expression of TLR5. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding TLR5. The compositions may also comprise antisense oligonucleotides targeted to nucleic acids encoding TLR5 in combination with other therapeutic and/or prophylactic compounds and/or compositions. Methods of using these compounds and compositions for down-regulating TLR5 expression and for prevention or treatment of diseases wherein modulation of TLR5 expression would be beneficial are provided.
    Type: Application
    Filed: November 4, 2009
    Publication date: May 6, 2010
    Applicant: IDERA PHARMACEUTICALS, INC.
    Inventors: Ekambar Kandimalla, Mallikarjuna Putta, Lakshmi Bhagat, Daqing Wang, Dong Yu, Sudhir Agrawal
  • Publication number: 20100111935
    Abstract: Antisense oligonucleotide compounds, compositions and methods are provided for down regulating the expression of TLR2. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding TLR2. The compositions may also comprise antisense oligonucleotides targeted to nucleic acids encoding TLR2 in combination with other therapeutic and/or prophylactic compounds and/or compositions. Methods of using these compounds and compositions for down-regulating TLR2 expression and for prevention or treatment of diseases wherein modulation of TLR2 expression would be beneficial are provided.
    Type: Application
    Filed: November 4, 2009
    Publication date: May 6, 2010
    Applicant: IDERA PHARMACEUTICALS, INC.
    Inventors: Lakshmi Bhagat, Ekambar Kandimalla, Mallikarjuna Putta, Daqing Wang, Dong Yu, Sudhir Agrawal
  • Patent number: 7709617
    Abstract: The invention provides optimized methods and compositions for enhancing the immune response caused by immunostimulatory compounds used for the treatment of disease such as, but not limited to, treatment of cancer, autoimmune disorders, asthma, respiratory allergies, food allergies and infectious diseases in a patient. The optimized methods according to the invention provide synergy between the therapeutic effects of immunostimulatory oligonucleotides and immunomer compounds in accordance with the invention, and the therapeutic effect of cytokine immunotherapy and/or chemotherapeutic agents and/or radiation.
    Type: Grant
    Filed: July 1, 2005
    Date of Patent: May 4, 2010
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Sudhir Agrawal
  • Publication number: 20100098685
    Abstract: The invention provides the use of TLR inhibitors or a pharmaceutically acceptable derivative thereof, optionally in combination with one or more lipid lowering composition, cholesterol lowering composition, diuretics, non-steroidal anti-inflammatory compounds (NSAIDs), antibodies, antisense oligonucleotides, TLR agonists, TLR antagonists, peptides, proteins or gene therapy vectors or combinations thereof for the prevention or treatment of hypercholesterolemia and/or hyperlipidemia and/or diseases associated therewith.
    Type: Application
    Filed: October 6, 2009
    Publication date: April 22, 2010
    Applicant: IDERA PHARMACEUTICALS, INC.
    Inventors: Fu-Gang Zhu, Ekambar Kandimalla, Sudhir Agrawal
  • Patent number: 7700570
    Abstract: The invention provides new methods for modulating specific CMI-inducing cytokines in vivo. Such new methods result in stimulation of the cytokines IL-6, IL-12 MIP-1? and MCP without substantially inducing undesired cytokines. The methods according to the invention are based upon administration of oligonucleotides containing particular structural motifs which lead to specific cytokine induction.
    Type: Grant
    Filed: June 12, 2002
    Date of Patent: April 20, 2010
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Sudhir Agrawal, Qiuyan Zhao
  • Patent number: 7671035
    Abstract: Disclosed are synthetic oligonucleotides complementary to nucleic acids encoding epidermal growth factor and methods of their use.
    Type: Grant
    Filed: May 7, 2002
    Date of Patent: March 2, 2010
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Sudhir Agrawal, Ekambar R. Kandimalla
  • Patent number: 7632822
    Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers and an immunostimulatory oligonucleotides for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers and an immunostimulatory oligonucleotides of the invention preferably comprise novel purines. The immunomers according to the invention further comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunomodulatory oligonucleotide and having an accessible 5? end.
    Type: Grant
    Filed: July 1, 2005
    Date of Patent: December 15, 2009
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Sudhir Agrawal, Lakshmi Bhagat, Dong Yu, Ekambar Kandimalla
  • Patent number: 7569554
    Abstract: The invention relates to the therapeutic use of immunostimulatory oligonucleotides and/or immunomers in combination with chemotherapeutic agents to provide a synergistic therapeutic effect.
    Type: Grant
    Filed: May 14, 2004
    Date of Patent: August 4, 2009
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Sudhir Agrawal, Daqing Wang, Lakshmi Bhagat, Dong Yu
  • Patent number: 7566702
    Abstract: The invention provides an immunostimulatory nucleic acid. In certain embodiments according to this aspect of the invention, the sequence of the immunostimulatory oligonucleotide and/or immunomer is at least partially self-complementary.
    Type: Grant
    Filed: September 22, 2005
    Date of Patent: July 28, 2009
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Sudhir Agrawal, Ekambar Kandimalla, Dong Yu
  • Patent number: 7517862
    Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5? end.
    Type: Grant
    Filed: August 25, 2004
    Date of Patent: April 14, 2009
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Sudhir Agrawal, Ekambar R. Kandimalla, Dong Yu, Lakshmi Bhagat
  • Patent number: 7498425
    Abstract: The invention provides an immunostimulatory nucleic acid. In certain embodiments according to this aspect of the invention, the sequence of the immunostimulatory oligonucleotide and/or immunomer is at least partially self-complementary.
    Type: Grant
    Filed: July 1, 2005
    Date of Patent: March 3, 2009
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Sudhir Agrawal, Ekambar Kandimalla, Dong Yu